Lurasidone Hydrochloride Tablet, Film Coated
Product Images NDC 70518-4260

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lurasidone Hydrochloride (NDC 70518-4260). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label for lurasidone hydrochloride 20 mg film-coated tablets, containing 30 tablets. The label includes the NDC number 70518-4260-00, manufacturer Ascend Labs LLC, and repackager RemedyRepack Inc. It also features storage instructions and safety warnings to keep out of reach of children.*

FDA Label Image

Lurasidone-structure (Lurasidone 1)

Chemical structure of lurasidone hydrochloride depicted as a two-dimensional molecular formula showing rings and functional groups, including nitrogen and oxygen atoms, and the hydrochloride (HCl) component.*

FDA Label Image

Lurasidone-fig2 (Lurasidone Fig2)

A horizontal error bar chart showing the impact of interacting drugs on lurasidone pharmacokinetics (PK). It displays fold changes and 90% confidence intervals for maximum concentration (Cmax) and area under the curve (AUC) relative to lurasidone alone. The chart lists strong CYP3A4 inhibitors (ketoconazole 400 mg/day), moderate CYP3A4 inhibitors (diltiazem 240 mg/day), and strong CYP3A4 inducers (rifampin 600 mg/day, lithium 600 mg BID) with their respective PK effects measured.*

FDA Label Image

Lurasidone-fig2 (Lurasidone Fig3)

A forest plot showing fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax, AUC, Trough) of various interacting drugs relative to the interactive drug alone. The plot includes data for digoxin, midazolam, oral contraceptives (ethinyl estradiol and norelgestromin), and lithium, illustrating changes in drug levels when administered together.*

FDA Label Image

Lurasidone-fig3 (Lurasidone Fig4)

A horizontal dot plot with error bars illustrating fold change and 90% confidence intervals for pharmacokinetic parameters (Cmax and AUC) under conditions of renal and hepatic impairment, as well as demographic population descriptions (gender and race). The x-axis shows change relative to a reference from 0 to 6, indicating variability in drug concentration metrics.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.